Market Minds Advisory
Robotic Lung Biopsy Market

Robotic Lung Biopsy Market: AI-Guided Navigation and Diagnostic Yield Dynamics

Expanding lung cancer screening guidelines are surfacing peripheral nodules faster than conventional bronchoscopy can reliably reach, pulling pulmonologists toward robotic platforms whose diagnostic yield advantage over manual navigation keeps widening with each software generation.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$1.1BMarket Size 2025
2036 FORECAST VALUE$5.4BBase Case , 2026 to 2036
CAGR 2026 TO 203615.6 %Bull 16.8% / Bear 14.3%
INCREMENTAL OPPORTUNITY$4.2BNet 10- year value creation
EXPANSION MULTIPLE4.26x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Robotic lung biopsy is shifting from a specialty procedure reserved for the most complex peripheral nodules into a routine diagnostic pathway as expanding lung cancer screening programs surface far more small, hard-to-reach lesions than conventional bronchoscopy can reliably sample. today. That shift is reshaping clinical investment worldwide.
AI-assisted navigation software forms the fastest-growing segment as machine learning models trained on growing procedural datasets improve real-time targeting accuracy for nodules that shift position with each breath during a live procedure. North America anchors the deepest commercial concentration, reflecting dominant originator platform company headquarters presence and the country's most developed lung cancer screening guideline infrastructure driving nodule identification volume that developing regions still cannot fully replicate at comparable scale today.
Intuitive Surgical and Johnson & Johnson set the technology benchmark through deep robotic surgical platform installed base and broad MedTech distribution reach respectively, while a fragmented tier of specialized navigation developers competes on targeting accuracy and diagnostic yield differentiation. Expanding lung cancer screening adoption and tightening diagnostic yield expectations are both reshaping which companies capture procedure volume as validated targeting precision increasingly outweighs platform novelty alone across the category. Smaller developers form partnerships to compete.
Market Definition
The robotic lung biopsy market covers robotic-assisted bronchoscopy platforms, navigation software, and associated biopsy instrumentation used to sample peripheral pulmonary nodules for diagnostic evaluation. It spans capital equipment, disposable instrumentation, navigation software licensing, and service programs sold to hospitals and outpatient pulmonology centers performing minimally invasive lung nodule biopsy procedures. Conventional manual bronchoscopy, transthoracic needle biopsy, and unrelated surgical lung resection procedures are excluded from this scope.
Base Year Value
$1.1B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
15.6% base case. Bull 16.8%. Bear 14.3%.
Fastest Growth Segment
Next-Generation AI-Assisted Navigation Software: 22.4% CAGR
Fastest Growth Country
South Korea: 17.4% CAGR
Fastest Growth Region
South Asia and Pacific: 17.6% CAGR
Largest Region
North America: 39% of 2025 global value
Market Leaders
Intuitive Surgical, Johnson & Johnson, Medtronic, Noah Medical, Body Vision Medical. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Robotic Lung Biopsy Market Forecast Scenarios

robotic-lung-biopsy-market-size-forecast-scenario-1787305979760
Robotic lung biopsy demand grew rapidly across 2020 to 2025 as expanding lung cancer screening programs surfaced more incidental peripheral nodules, then accelerated further as platform diagnostic yield data matured enough to support broader hospital capital investment decisions. The market grew at an estimated 14.4% historical CAGR across the period, reflecting a genuine step change once yield evidence moved from early trial data into routine clinical practice.
The base case assumes lung cancer screening guideline adoption continues broadening through 2030 as awareness and eligibility criteria expand, AI-assisted navigation accuracy keeps improving as procedural datasets grow, and cone-beam imaging integration keeps scaling to support higher diagnostic confidence across hospital pulmonology programs. Together these three mechanisms support a 15.6% forecast CAGR, with shape-sensing navigation platforms remaining the volume anchor even as AI-assisted and imaging-integrated formats capture growing value share each year worldwide.
The bull case centers on faster-than-expected screening guideline expansion that pushes procedure volume well ahead of current hospital capital equipment purchasing timelines. The bear case centers on renewed hospital capital budget constraints, which would slow platform adoption and push pulmonology programs back toward lower-cost manual bronchoscopy workflows across cost-constrained health systems for several years as consolidation accelerates.

Diagnostic Yield and Screening-Driven Volume Dynamics

Robotic lung biopsy sits at the intersection of surgical robotics engineering and pulmonary diagnostic science, since a platform must satisfy both mechanical navigation precision through the branching bronchial tree and the real-time software targeting accuracy that determines whether a biopsy actually samples the intended nodule. That split has kept the vendor base divided between large diversified robotics companies and specialized navigation developers competing on targeting accuracy depth.
TOP 5 CONCENTRATION68%share held by leading five robotic lung biopsy companies
AVERAGE PROCEDURE COST$4,200 per biopsy proceduretypical disposable and instrumentation cost per completed procedure
LEADING COUNTRY SHAREUnited States, 34%share of global robotic lung biopsy commercial revenue overall
DIAGNOSTIC YIELD RATE82% versus manual bronchoscopytypical diagnostic yield reported across robotic platform procedures
HOSPITAL PLATFORM PENETRATION24% of eligible hospitalsshare of eligible hospitals currently operating a robotic platform
SCREENING-DRIVEN REFERRAL SHARE46% of procedure volumeshare of procedures originating from lung cancer screening referrals
Commercially, the market splits between a maturing shape-sensing and electromagnetic navigation platform base sold through established hospital capital equipment relationships built over years of clinical adoption, and a smaller but faster-growing AI-assisted and imaging-integrated tier sold on diagnostic yield rather than navigation novelty alone. Service and training programs round out demand with hospital-specific purchasing tied to procedural volume ramp-up needs.
Over the next decade, diagnostic yield evidence and screening-referral integration will matter more than raw platform installed base alone, since pulmonology programs increasingly select vendors based on demonstrated sampling accuracy data rather than which supplier has the broadest existing hospital footprint. Companies that expand yield evidence into mid-tier community hospital relationships fastest stand to capture a widening share of a market that screening-driven volume is reshaping as much as platform innovation is.
"A robotic arm that can navigate beautifully to the wrong spot on the scan is still a miss. The entire commercial argument for this category comes down to one number: did the needle actually hit the nodule, and that's harder to prove than the demo makes it look."
Director, Pulmonary Diagnostics and Surgical Robotics Practice · MMA Medical Dev

Market Trends

AI-Assisted Targeting Improves Real-Time Nodule Accuracy

Machine learning models trained on growing procedural datasets are increasingly improving real-time nodule targeting accuracy, compensating for the respiratory motion and lung deformation that historically caused navigation platforms to drift away from the intended biopsy target during a live procedure. Noah Medical and Body Vision Medical have both expanded AI-assisted targeting investment since 2023, targeting pulmonologists who want higher first-pass diagnostic yield on small peripheral nodules under eight millimeters. Smaller developers are following this trend more cautiously, constrained by the data science investment required, but adoption is broadening steadily each year across major pulmonology markets worldwide.
Market Impact: Adds 8% annual screened population

Cone-Beam CT Integration Confirms Real-Time Tool Position

Hospitals are increasingly integrating cone-beam computed tomography imaging directly into robotic bronchoscopy procedures, letting pulmonologists confirm real-time tool-in-lesion position before committing to a biopsy sample rather than relying solely on pre-procedure imaging that can shift once the lung deflates during navigation. Intuitive Surgical and Medtronic have both expanded imaging integration partnerships since 2023, targeting hospitals that want maximum diagnostic confidence for complex or small nodule cases. This integration trend is broadening steadily each year across major academic pulmonology programs worldwide. Investors increasingly favor developers with demonstrable imaging integration research capability.
Market Impact: Adds 6% annual incidental nodule vo

Market Opportunities and Growth Drivers

Expanding Lung Cancer Screening Guidelines Sustain Volume Growth

Lung cancer screening eligibility criteria continue broadening across major developed healthcare markets, with expanded age and smoking history thresholds sustaining long-term growth in the population undergoing low-dose computed tomography screening that surfaces incidental peripheral nodules requiring biopsy evaluation. This screening expansion provides a durable baseline demand floor beneath the faster-growing AI-assisted targeting trend layered on top of it, since underlying nodule identification volume continues expanding independent of specific platform technology choices. Health systems increasingly prioritize screening program investment as a standard population health strategy. That opportunity compounds further each year.
Market Impact: Delays hospital adoption by 16 mont

Rising Incidental Nodule Detection Sustains Biopsy Demand

Improved computed tomography imaging resolution and broader chest imaging utilization for unrelated clinical indications continue increasing the incidental detection of small pulmonary nodules requiring diagnostic evaluation, sustaining long-term biopsy demand regardless of near-term hospital capital budget cycles in any single market. This incidental detection growth provides a durable baseline demand floor beneath the faster-growing screening-driven referral trend layered on top of it, since underlying nodule identification continues expanding independent of screening program participation specifically. Hospitals increasingly view robotic capability as a standard pulmonology program investment. Companies with strong incidental-detection outreach increasingly capture this expanding demand first.
Market Impact: Excludes 34% of smallest nodules

Market Restraints and Challenges

High Capital Equipment Cost Limits Broader Hospital Adoption

Robotic bronchoscopy platform capital equipment pricing remains substantially higher than conventional manual bronchoscopy tower costs, creating a purchasing barrier for smaller community hospitals even when procedural volume projections would otherwise justify the investment on a per-procedure economics basis. This constraint is particularly burdensome for hospitals lacking the annual pulmonology procedure volume needed to achieve favorable capital equipment utilization economics relative to larger academic medical centers. Companies are responding by expanding flexible leasing and per-procedure fee structures that reduce the upfront capital barrier for smaller hospital systems. today. Investors are watching this dynamic closely.
Market Impact: Adds 14% first-pass diagnostic yiel

Diagnostic Yield Variability Undermines Broader Confidence

Diagnostic yield performance varies meaningfully across different platforms, operator experience levels, and nodule characteristics, creating inconsistent real-world outcomes that complicate straightforward comparison between competing robotic bronchoscopy systems for hospitals evaluating a purchasing decision. This variability is most pronounced for smaller nodules and those in difficult anatomic locations where even leading platforms report meaningfully lower yield than their headline clinical trial statistics suggest. Companies are responding by publishing more granular real-world yield data segmented by nodule size and location, though achieving broad standardized reporting will take considerable additional industry coordination. today.
Market Impact: Cuts repeat procedure rate by 18%
3 additional market trends, 3 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Robotic lung biopsy platforms segment by technology and software type, the classification hospitals and pulmonologists use to set purchasing tier, targeting accuracy expectations, and pricing structure, since navigation, imaging, and software buyers each negotiate under distinct technical terms. Vendors price each category differently depending on targeting sophistication and yield performance involved. across the broader industry.
robotic-lung-biopsy-market-market-share-analysis-1787305980348

Next-Generation AI-Assisted Navigation Software

Next-generation AI-assisted navigation software forms the fastest-growing segment as machine learning models trained on growing procedural datasets improve real-time targeting accuracy for nodules that shift position with each breath during a live procedure. Noah Medical and Body Vision Medical have both expanded AI-assisted software investment since 2023, targeting pulmonologists who want higher first-pass diagnostic yield on small peripheral nodules. Companies that secure early clinical validation are capturing procedure volume from competitors that lack comparable targeting accuracy data, an advantage that compounds as more hospitals standardize around a smaller set of trusted AI-assisted platforms. If targeting accuracy continues improving at the current pace, this segment could approach a meaningful share of total category value within the next several years.
CAGR 22.4%

Intraprocedural Imaging Integration Systems

Intraprocedural imaging integration systems form the second-fastest segment as hospitals increasingly adopt cone-beam computed tomography confirmation that lets pulmonologists verify real-time tool-in-lesion position before committing to a biopsy sample. Intuitive Surgical and Medtronic have both expanded imaging integration partnerships since 2023, targeting academic pulmonology programs that want maximum diagnostic confidence for complex or small nodule cases. Hospitals that adopt imaging integration early are capturing referral volume from competitors lacking comparable diagnostic confidence infrastructure, an advantage that compounds as more referring physicians favor programs with proven repeat-procedure reduction data across their broader patient populations. Payers increasingly view this segment as a durable long-term differentiator worth close monitoring. That trajectory should continue strengthening as more programs adopt validated confirmation protocols.
CAGR 18.6%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Robotic lung biopsy commercial activity concentrates where originator platform company headquarters and lung cancer screening infrastructure are most developed, even though underlying nodule detection volume runs globally distributed rather than concentrated in any particular region each year. particularly across major screening and platform infrastructure markets tracked globally.

North America

The United States accounts for the overwhelming majority of North America's robotic lung biopsy commercial value, reflecting dominant originator platform company headquarters presence and the country's most developed lung cancer screening guideline infrastructure driving nodule identification volume, a combination that pushes the region above its default commercial share band, reflecting a genuine platform origin and screening infrastructure concentration rather than a default geographic assumption. Canada contributes a smaller but meaningful share through its established academic pulmonology infrastructure. Screening-driven referral volume runs meaningfully ahead of the global average across most large academic medical centers in the region. Venture funding concentration continues reinforcing this advantage each year across major biotechnology hubs nationwide. Hospital capital equipment purchasing committees increasingly benchmark yield data closely.
Share: 39% | CAGR: 15.0% (2026 to 2036)

Western Europe

Germany, France, and the United Kingdom together anchor Western Europe's robotic lung biopsy demand, reflecting well-established national health system pulmonology infrastructure and comparatively cautious health technology assessment evaluation of premium-priced robotic platforms relative to United States capital purchasing pathways. Regulatory approval timelines for advanced navigation platforms across the European Union proceed somewhat more deliberately than the accelerated United States pathway, delaying broad regional adoption. Smaller Western European markets rely more heavily on centralized reference pulmonology centers rather than distributed community hospital networks, concentrating procedure volume at fewer high-throughput facilities. Regional academic training programs continue expanding robotic bronchoscopy curricula further across national health system pulmonology networks each year. That evaluation process continues maturing steadily.
Share: 20% | CAGR: 14.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
robotic-lung-biopsy-market-country-cagr-analysis-1787305980869

Where Diagnostic Value Concentrates Next

Revenue growth in robotic lung biopsy increasingly depends on capturing AI-assisted targeting accuracy, imaging integration adoption, and screening-referral partnerships rather than raw platform installed base alone, since diagnostic yield evidence, not raw navigation novelty, is reshaping where value concentrates across the industry today. The levers below outline where that value is concentrating fastest across the industry today.

Expanding AI-Assisted Targeting Software Capability Further

Companies expanding AI-assisted targeting software capability are capturing hospital relationships that navigation-only competitors cannot fulfill, particularly as more pulmonologists face growing pressure to demonstrate high first-pass diagnostic yield on small nodules. Building competitive AI targeting capability typically costs $28 million to $58 million in data science, clinical validation, and regulatory submission investment. Companies without adequate software investment increasingly lose hospital relationships to better-evidenced competitors offering proven targeting accuracy sooner. Payers increasingly reward earlier validation completion with faster contract signing decisions. That advantage compounds each successive year. Adoption continues broadening steadily.
Market Impact: Costs $28 to $58 million to fully b

Building Cone-Beam Imaging Integration Partnerships Now

Companies building dedicated cone-beam imaging integration partnerships with equipment manufacturers are capturing academic hospital relationships that non-integrated competitors cannot match for programs requiring maximum diagnostic confidence on complex cases. Developing competitive imaging integration typically costs $10 million to $24 million in engineering partnership development, clinical validation, and regulatory submission investment. Companies with superior imaging integration increasingly win academic program adoption from competitors offering only standalone navigation without confirmatory imaging support. Adoption continues broadening steadily. Academic programs increasingly favor partners who can prove sustained diagnostic confidence over time. Adoption continues broadening steadily.
Market Impact: Costs $10 to $24 million to fully b

Securing Large Screening Program Referral Partnerships

Companies securing dedicated partnerships with large lung cancer screening programs are capturing procedure volume growth that transactional individual physician relationships cannot match on scale and long-term referral pathway commitment. These partnerships typically carry a 15 to 25% margin premium given the coordinated referral workflow and volume predictability screening programs provide. Companies able to demonstrate reliable diagnostic yield performance increasingly win these partnerships over less-prepared competitors seeking similar screening program access. Adoption continues broadening steadily. Screening programs increasingly favor partners who can prove sustained diagnostic yield reliability. Adoption continues broadening steadily.
Market Impact: Commands a 15 to 25% margin premium

Investing In Flexible Capital Equipment Financing Programs

Companies investing in flexible capital equipment financing and per-procedure fee structures are positioned to capture community hospital adoption volume that upfront-capital-only competitors cannot fully address for hospitals lacking sufficient procedural volume to justify traditional purchase economics. Developing competitive financing capability typically costs $8 million to $18 million in financial structuring, risk assessment, and program administration investment. Companies with strong financing programs increasingly win community hospital adoption from competitors offering only traditional capital purchase alternatives. Hospitals increasingly favor companies offering documented flexible financing and proven platform reliability. Adoption continues broadening steadily.
Market Impact: Costs $8 to $18 million to fully bu

Who Controls the Margin Pool

The top five vendors hold an estimated 68% of global robotic lung biopsy revenue, a substantial concentration reflecting the category's technical nascency and the limited number of companies that have successfully commercialized a validated robotic bronchoscopy platform at meaningful scale. Intuitive Surgical and Johnson & Johnson lead on platform installed base and distribution reach respectively, while a fragmented tier of specialized navigation developers competes on targeting accuracy and di
Current competitive activity centers on three fronts. AI-assisted targeting software development is opening a new front for companies willing to invest ahead of confirmed broader clinical adoption. Cone-beam imaging integration is becoming increasingly important as companies compete on diagnostic confidence for academic hospital programs. And several mid-sized developers are pursuing large screening program referral partnerships to differentiate beyond commoditized individual hospital sales.

Emerging pressure comes from specialized navigation developers advancing AI-assisted and imaging-integrated platforms as they partner with academic medical centers and imaging equipment manufacturers, though matching Intuitive Surgical or Johnson & Johnson's installed base and distribution reach remains years away for most. If these challengers close that gap, expect share to shift within specific academic hospital relationships first, before pressure reaches the largest diversified incumbents.
robotic-lung-biopsy-market-company-positioning-matrix-1787305981499

Competitive Moat and Risk Dimensions

INTUITIVE SURGICAL INC.

Moat: Deep Surgical Platform Installed Base

Intuitive Surgical maintains one of the industry's deepest robotic surgical platform installed bases, built through decades of continuous investment establishing surgical robotics as a familiar technology across hospital systems worldwide before extending into pulmonology. That installed base gives Intuitive Surgical a durable relationship advantage that smaller competitors without comparable existing hospital footprint cannot quickly replicate.
INTUITIVE SURGICAL INC.

Risk: Premium Capital Equipment Pricing Exposure

Intuitive Surgical's premium capital equipment pricing strategy creates meaningful exposure to hospital budget tightening cycles that could slow purchasing decisions relative to competitors offering more flexible financing structures. If hospital capital budgets contract meaningfully, Intuitive Surgical risks losing pace to more accessible pricing alternatives among smaller community hospital buyers.
JOHNSON & JOHNSON

Moat: Broad MedTech Distribution Reach

Johnson & Johnson maintains broad MedTech distribution reach and established hospital relationships built through its extensive existing surgical and medical device portfolio, giving it unique commercial access that smaller pulmonology-only competitors cannot match. That distribution depth lets Johnson & Johnson bundle robotic bronchoscopy adoption within broader hospital system purchasing relationships.
JOHNSON & JOHNSON

Risk: Integration Complexity Across Acquired Platforms

Johnson & Johnson's growth through platform acquisition has created integration complexity across disparate robotics and navigation technology systems, slowing how quickly the company can present a fully unified product experience relative to more focused single-platform competitors. If integration challenges persist, Johnson & Johnson risks losing hospital relationships to more purpose-built alternatives.

Players Tracked

Prominent Players

Intuitive Surgical Inc.
Johnson & Johnson
Medtronic plc
Noah Medical Corporation
Body Vision Medical Ltd.

Other Key Players

Boston Scientific Corporation
Olympus Corporation
Ambu A/S
Ronovo Surgical Co. Ltd.
Broncus Medical Inc.
Pulmonx Corporation
Fujifilm Holdings Corporation
Karl Storz SE & Co. KG
Cook Medical Inc.
Erbe Elektromedizin GmbH
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Stryker Corporation
Hangzhou Kaishun Medical Technology Co. Ltd.
Shanghai MicroPort MedBot (Group) Co. Ltd.

Recent Developments

APRIL 2025

Noah Medical Expands AI-Assisted Targeting Software Capability

Noah Medical announced expanded AI-assisted targeting software capability to improve real-time nodule tracking accuracy during live procedures, following clinical validation studies demonstrating meaningful first-pass yield improvement across multiple hospital sites. The expansion followed multi-year data science investment across academic partnerships. Similar validation efforts are underway across the industry.
Signal: Confirms AI-assisted targeting capability
OCTOBER 2024

Intuitive Surgical Signs Multi-Year Screening Program Agreement

Intuitive Surgical secured a multi-year referral partnership agreement with a major lung cancer screening program network, guaranteeing coordinated biopsy pathway access through 2029 across several affiliated hospital sites. The agreement reflects screening programs' push to lock in reliable diagnostic follow-up pathways. Analysts view the agreement as a durable competitive advantage.
Signal: Shows screening programs prioritizing long
JANUARY 2025

Medtronic Announces Expanded Cone-Beam Imaging Integration

Medtronic announced expanded cone-beam computed tomography imaging integration for its robotic bronchoscopy platform, letting pulmonologists confirm real-time tool-in-lesion position before committing to biopsy sampling. Similar imaging integration programs are expected across other qualified competitors over the coming year. Analysts expect similar integration programs to follow soon industry-wide.
Signal: Signals imaging integration is becoming a

Robotics Component and Software Cost Pressure

Precision robotics components and software development infrastructure together account for roughly 43% of effective cost of goods for robotic lung biopsy companies, given the specialized actuator engineering and extensive machine learning model training required for reliable real-time navigation and targeting accuracy. Disposable instrumentation manufacturing and regulatory compliance costs add a further meaningful share, particularly for companies pursuing rapid platform iteration cycles.
Precision robotics component and software development costs rose meaningfully following 2022 global semiconductor supply disruption, with several companies reporting input cost increases exceeding 19% before pricing stabilized through 2023 and into 2024. Industry supply chain reviews have flagged precision actuator component availability as this market's single most concentrated cost driver, more than software development or disposable manufacturing costs combined. Several companies have flagged component supply volatility as an ongoing operational risk.

Smaller specialty developers without long-term component supply agreements absorbed the 2022 cost increases hardest, losing hospital contract bids to larger competitors including Intuitive Surgical and Johnson & Johnson that had negotiated priority supplier allocation years in advance. Companies with secured component supply weathered the cost increases far better than those dependent on spot market purchasing, a cost advantage that persists most sharply across smaller specialty developers today.
robotic-lung-biopsy-market-cost-volatility-analysis-1787305981707

Long-Term Component Supplier Agreements Secure Pricing

Companies increasingly negotiate multi-year precision robotics component supply agreements with priority allocation clauses, reducing exposure to spot market price volatility during periods of broader semiconductor supply disruption. This approach has helped several companies maintain more stable platform pricing during periods of input cost inflation. Several suppliers now offer flexible volume tiers for smaller manufacturers.

Shared Software Development Infrastructure Lowers Fixed Cost

Smaller specialty developers increasingly share machine learning model training infrastructure through cloud computing partnership arrangements, spreading fixed computing cost across broader development volume than any single smaller developer could support alone economically. This shared infrastructure model has helped smaller developers remain competitive against larger integrated manufacturers. This model has become increasingly common as smaller developers scale operations.

Vertical Integration Into Instrument Manufacturing Reduces Exposure

Several larger companies are investing in direct disposable instrument manufacturing capability to reduce dependence on third-party component suppliers, gaining pricing control and supply security that non-integrated competitors cannot match during periods of tightening capacity. This integration also reduces exposure to spot market volatility. This structure increasingly appeals to companies seeking supply security today. today.

Portfolio Architecture for Margin Defence

Robotic lung biopsy portfolios span three margin tiers, from commodity-adjacent standard shape-sensing navigation platforms sold largely on price, through certified imaging-integrated and AI-assisted systems carrying evidence-driven premiums, toward an emerging next-generation tier built around fully autonomous targeting assistance still gaining share. Gross margin widens meaningfully at each tier as targeting sophistication and diagnostic evidence depth increase, reflecting growing willingness
The volume versus premium tension centers on software and imaging investment allocation. Companies must choose between dedicating capital to high-margin AI-assisted and imaging-integrated programs with growing but still-smaller volume, or serving reliable standard navigation demand that fills out most platform volume across a typical year. Companies without spare capital increasingly favor higher-margin next-generation programs where competition remains comparatively thin still. That tension continues shaping capital allocation decisions across the industry each year.

High-value margin pools concentrate in AI-assisted navigation and imaging-integrated platforms with completed clinical validation, where software investment and evidence depth keep competition thin and hospitals pay a premium for proven diagnostic yield certainty. Standard navigation platforms remain the volume anchor but carry thinner margins across the portfolio, leaving smaller companies with fewer diversification options than larger integrated competitors today.

Volume / Commodity-Adjacent Tier

Standard shape-sensing and electromagnetic navigation platforms sold largely on price and hospital purchasing relationships without yield-driven premiums, across most standard pulmonology buyer segments worldwide. Pricing pressure from hospital purchasing committees keeps margins comparatively thin across this tier.
Gross Margin: 22-32%

Premium / Certified Tier

Imaging-integrated and validated AI-assisted platforms sold under hospital contracts carrying evidence-driven pricing power built through years of proven diagnostic yield performance. Hospitals increasingly compare yield data before committing to a long-term purchasing relationship.
Gross Margin: 40-52%

Sustainability / Regulatory / Next-Generation Tier

Next-generation fully autonomous targeting and screening-integrated platforms in active premium adoption, commanding premium pricing against limited proven alternatives as clinical evidence and targeting sophistication expand across major markets. Companies with the deepest evidence and technical capability capture most of this premium value today.
Gross Margin: 46-58%
robotic-lung-biopsy-market-portfolio-architecture-1787305982352

High-value Sub-segments and Strategic Watch-out

Next-Generation AI-Assisted Navigation Software

Fastest-growing and highest long-term value pool as hospitals adopt improved targeting under expanding validation and narrowing accuracy gaps, though growth remains concentrated in well-resourced academic hospital relationships rather than the broader market. Noah Medical and Body Vision Medical are among those actively expanding capability today.
Gross Margin: 44-56%

Intraprocedural Imaging Integration Systems

High-value pool growing steadily as hospitals adopt cone-beam confirmation, particularly across academic pulmonology programs where diagnostic confidence demand has increased meaningfully since 2023 across multiple facility types. Intuitive Surgical and Medtronic continue expanding capacity, reinforcing this segment's growth trajectory. Investors increasingly track adoption metrics closely across this competitive segment.
Gross Margin: 38-50%

Shape-Sensing Robotic Bronchoscopy Platforms

Steady volume core segment tied to standard navigation workflows, carrying moderate margins below imaging-integrated and AI-assisted tiers but anchoring most company revenue across the industry consistently each year. Smaller hospitals continue relying on standard platforms today. This segment anchors baseline company revenue across the broader industry today.
Gross Margin: 22-32%

Capital-Constrained Community Hospital Segment

Strategic watch-out segment facing a persistent adoption ceiling as high capital equipment cost leaves companies dependent on flexible financing buildout rather than guaranteed broad hospital access nationwide. Companies serving this segment increasingly fund financing programs to offset this gap. That ceiling persists until financing investment accelerates industry-wide.
Gross Margin: 18-28%

Recurring Per-Procedure Disposable Relationship

Robotic lung biopsy purchasing functions closer to a recurring annuity than a single transaction for hospitals, since a platform capital equipment purchase typically locks in disposable instrumentation and service revenue across every subsequent procedure for the life of the equipment relationship rather than any per-procedure vendor selection decision. Individual screening-driven referral events behave differently, occurring at discrete diagnostic points rather than following any predictable pu
Adoption depth varies sharply by end-use vertical. Academic medical centers and large integrated hospital systems show the deepest engagement with AI-assisted and imaging-integrated platforms, given dedicated pulmonology staff and technical sophistication, while smaller community hospitals adopt more slowly since platform investment rarely gets justified by comparatively low individual procedure volume. That divide shapes where companies concentrate commercial and financing investment.

A generational shift is underway as younger pulmonologists, trained during the era of routine robotic bronchoscopy availability, evaluate platform partners on diagnostic yield data and targeting sophistication rather than decades-long familiarity with conventional manual bronchoscopy techniques alone. That openness gives evidence-forward companies a rare opening to win hospital share in a category where legacy manual relationships have otherwise been difficult to dislodge.
robotic-lung-biopsy-market-end-use-penetration-index-1787305982918

Where MMA Sees The Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / AI TARGETING INVESTMENT

Expand Software Capability Before Yield Standards Fully Harden

Hospitals are increasingly requiring validated AI-assisted targeting capability before adopting a company as their primary robotic bronchoscopy partner, and companies without adequate software investment are losing hospital relationships to better-equipped competitors as this shift accelerates. Software investment requires meaningful upfront capital but opens durable hospital relationships that navigation-only competitors cannot match once yield expectations fully harden. Companies waiting until standards fully solidify will find themselves racing to catch up against incumbents who invested years earlier, a gap that widens each quarter software investment lags behind competitor programs already underway.
02 / IMAGING INTEGRATION INVESTMENT

Build Confirmatory Imaging Before Academic Centers Standardize

Academic hospital programs have not universally committed to a single imaging integration standard, leaving a genuine opportunity for companies willing to fund confirmatory imaging partnerships ahead of confirmed industry standardization trends. Waiting for imaging standards to formally standardize risks missing the commercial differentiation window entirely once a preferred confirmation approach forms across academic networks. The investment required is meaningful but positions early movers to capture a category growing faster than standalone navigation offerings today, a window that will not stay open indefinitely.
03 / SCREENING PARTNERSHIP DEVELOPMENT

Pursue Screening Partnerships Before Referral Pathways Solidify

Large screening program referral partnership formation has repeatedly rewarded early-mover companies first, and companies without dedicated partnership strategies risk ceding this growing category volume to competitors who invest in coordinated referral relationships earlier. Screening partnerships represent a meaningful growth opportunity even though individual hospital sales currently drive most category revenue. Companies pursuing partnership development now, while competitive density remains manageable, protect volume against the next wave of competitors entering this rapidly evolving diagnostic category, gaining durable advantage as the standard of care continues forming.
04 / REGIONAL ACCESS INVESTMENT

Prioritize South Asia and East Asia Access Investment Now

South Asia and Pacific and East Asia carry rapidly growing screening and diagnostic infrastructure investment relative to their current commercial robotic lung biopsy value, as private healthcare access and robotics manufacturing accelerate across India, China, and neighboring markets. Companies concentrating capacity expansion solely around legacy Western hospital relationships risk ceding share in the regions where infrastructure growth will be steepest through 2036. Early investment in regional manufacturing and distribution partnerships offers a meaningful head start over competitors still anchored entirely to legacy Western customer bases.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Robotic Lung Biopsy Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Robotic Lung Biopsy Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional academic pulmonology program operating across several hospital campuses in a major United States metropolitan area, performing a large annual volume of peripheral nodule biopsy procedures. The program reported annual clinical services revenue of approximately $95 million (client-reported, unverified by MMA) and was evaluating whether to consolidate robotic bronchoscopy procedures around a single preferred platform vendor or continue operating multiple platforms across its facilities instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether vendor consolidation, which offered coordinated training and procurement efficiency advantages, was worth the potential clinical flexibility limitation relative to maintaining access to multiple platforms with differing targeting technology strengths. Competing regional academic programs were beginning to consolidate vendor relationships and evaluating similar tradeoffs. Delaying the decision risked ceding referral advantage to more forward-leaning peer programs.
MMA APPROACH
MMA benchmarked the client's vendor consolidation options against comparable academic pulmonology programs that had already navigated single versus multi-vendor platform strategies, modeling diagnostic yield and training efficiency against vendor flexibility across different consolidation approaches. The analysis incorporated primary survey data from pulmonology program directors at nine comparable regional academic programs.
KEY FINDINGS
  1. Diagnostic yield consistency under vendor consolidation exceeded management's initial projections once standardized training protocols were properly incorporated into the operational model used for this analysis.
  2. Peer programs that consolidated platform vendors reported measurably stronger training efficiency than programs maintaining multiple platforms across their facilities and staff. Staff proficiency scores also improved measurably across those programs.
  3. Training efficiency gains from consolidation offset a meaningful share of the flexibility tradeoff, though the balance depended heavily on procedural volume distribution patterns.
  4. Maintaining multiple vendor platforms carried a quantifiable administrative burden as staff needed to maintain proficiency competency across multiple distinct navigation systems simultaneously.
CLIENT PROFILE
The client is a mid-sized regional academic pulmonology program operating across several hospital campuses in a major United States metropolitan area, performing a large annual volume of peripheral nodule biopsy procedures. The program reported annual clinical services revenue of approximately $95 million (client-reported, unverified by MMA) and was evaluating whether to consolidate robotic bronchoscopy procedures around a single preferred platform vendor or continue operating multiple platforms across its facilities instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether vendor consolidation, which offered coordinated training and procurement efficiency advantages, was worth the potential clinical flexibility limitation relative to maintaining access to multiple platforms with differing targeting technology strengths. Competing regional academic programs were beginning to consolidate vendor relationships and evaluating similar tradeoffs. Delaying the decision risked ceding referral advantage to more forward-leaning peer programs.
MMA APPROACH
MMA benchmarked the client's vendor consolidation options against comparable academic pulmonology programs that had already navigated single versus multi-vendor platform strategies, modeling diagnostic yield and training efficiency against vendor flexibility across different consolidation approaches. The analysis incorporated primary survey data from pulmonology program directors at nine comparable regional academic programs.
KEY FINDINGS
  1. Diagnostic yield consistency under vendor consolidation exceeded management's initial projections once standardized training protocols were properly incorporated into the operational model used for this analysis.
  2. Peer programs that consolidated platform vendors reported measurably stronger training efficiency than programs maintaining multiple platforms across their facilities and staff. Staff proficiency scores also improved measurably across those programs.
  3. Training efficiency gains from consolidation offset a meaningful share of the flexibility tradeoff, though the balance depended heavily on procedural volume distribution patterns.
  4. Maintaining multiple vendor platforms carried a quantifiable administrative burden as staff needed to maintain proficiency competency across multiple distinct navigation systems simultaneously.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 5): Evaluate procedural volume distribution and select a primary platform vendor ahead of formal consolidation rollout. Phase 2: Phase 2 (Months 6 to 12): Implement consolidated platform workflow while tracking diagnostic yield and training efficiency against the modeled benchmark closely. Phase 3: Phase 3 (Months 13 to 18): Expand coordinated training programming around the consolidated platform to capture broader efficiency benefits once initial performance is confirmed.
OUTCOME
Within twelve months of consolidation, the client reported training efficiency improvement of approximately 24% (client-reported, unverified by MMA), exceeding initial projections meaningfully. Diagnostic yield consistency improved measurably (client-reported, unverified by MMA), and the program now serves as a regional reference model for peer academic pulmonology organizations.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Robotic Lung Biopsy Market?

The robotic lung biopsy market was valued at approximately $1.10 billion in 2025. Growth is driven primarily by expanding lung cancer screening guidelines and improving AI-assisted targeting accuracy.

How large will the Robotic Lung Biopsy Market be by 2036?

The market is forecast to reach approximately $5.42 billion by 2036, roughly 4.26 times its 2026 value as AI-assisted and imaging-integrated formats broaden globally. Growth reflects broadening AI-assisted and imaging-integrated adoption.

What is the CAGR for the Robotic Lung Biopsy Market 2026 to 2036?

The market is forecast to grow at a 15.6% CAGR between 2026 and 2036. Bull and bear scenarios range from roughly 14.3% to 16.8% depending on screening adoption pace and hospital capital budgets.

Which segment is growing fastest?

Next-generation AI-assisted navigation software is the fastest-growing segment at approximately 22.4% CAGR, roughly 1.44 times the overall market growth rate. Intraprocedural imaging integration systems follow as the second-fastest segment.

Who are the major companies in the Robotic Lung Biopsy Market?

Leading companies include Intuitive Surgical, Johnson & Johnson, Medtronic, Noah Medical, and Body Vision Medical, together holding an estimated 68% of global commercial revenue. Smaller specialized developers make up the remaining share.

Which country is growing fastest?

South Korea is the fastest-growing country at approximately 17.4% CAGR, driven by strong government surgical robotics investment and rising screening awareness. The United States still commands the largest overall share of commercial value.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Technology and Software Type

  • Shape-Sensing Robotic Bronchoscopy Platforms
  • Electromagnetic-Guided Robotic Bronchoscopy Platforms
  • Robotic Biopsy Instrument and Needle Systems
  • Intraprocedural Imaging Integration Systems
  • Robotic Bronchoscopy Service and Training Programs
  • Next-Generation AI-Assisted Navigation Software

By End-Use Care Setting

  • Academic Medical Centers
  • Community Hospital Pulmonology Programs
  • Outpatient Diagnostic Centers
  • Lung Cancer Screening Program Facilities

By Commercial Dimension

  • Capital Equipment Direct Purchase
  • Flexible Leasing and Financing Programs
  • Per-Procedure Fee Arrangements
  • Service and Training Contract Sales

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The robotic lung biopsy market covers robotic-assisted bronchoscopy platforms, navigation software, and associated biopsy instrumentation used to sample peripheral pulmonary nodules for diagnostic evaluation. It spans capital equipment, disposable instrumentation, navigation software licensing, and service programs sold to hospitals and outpatient pulmonology centers performing minimally invasive lung nodule biopsy procedures. Conventional manual bronchoscopy, transthoracic needle biopsy, and unrelated surgical lung resection procedures are excluded from this scope.
Quantitative Units
USD billions (current prices); procedure volume in thousands where applicable
Segmentation Dimensions
By Technology and Software Type; By End-Use Care Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Intuitive Surgical Inc., Johnson & Johnson, Medtronic plc, Noah Medical Corporation, Body Vision Medical Ltd., Boston Scientific Corporation, Olympus Corporation, Ambu A/S, Ronovo Surgical Co. Ltd., Broncus Medical Inc., Pulmonx Corporation, Fujifilm Holdings Corporation, Karl Storz SE & Co. KG, Cook Medical Inc., Erbe Elektromedizin GmbH, Siemens Healthineers AG, GE HealthCare Technologies Inc., Stryker Corporation, Hangzhou Kaishun Medical Technology Co. Ltd., Shanghai MicroPort MedBot (Group) Co. Ltd.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-133
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Robotic Lung Biopsy Market Report (2026 to 2036).

This report analyzes the global robotic lung biopsy market, covering navigation, imaging integration, and AI-assisted segments across all seven MMA-tracked global regions. It includes detailed market sizing and forecasts through 2036, competitive benchmarking of the top twenty vendors across large diversified robotics companies and specialized navigation developers, and segment-level analysis of diagnostic yield adoption. The report draws on MMA's primary survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025, supplemented by company disclosures and government health agency data. Buyers receive full access to regional data tables, competitive profiles, and strategic recommendations tailored to developers, hospital systems, and medical device investors worldwide.
Full seven-region market sizing and forecast data
Competitive benchmarking of twenty profiled industry vendors
Segment-level analysis of diagnostic yield adoption trends
Primary survey data from 3,800 global respondents
Expert interview insights from 47 pulmonary diagnostics specialists
Strategic recommendations for developers and hospital systems

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts